For persons receiving chemotherapy of high emetic risk , there is no group of patients for whom agents of lower therapeutic index are appropriate first-choice antiemetics .
In all patients receiving cisplatin and all other agents of high emetic risk , the two-drug combination of dexamethasone and aprepitant is recommended for the prevention of delayed emesis .
The Up date Committee no longer recommends the combination of a 5-HT3 serotonin receptor antagonist and dexamethasone for the prevention of delayed emesis after chemotherapeutic agents of high emetic risk .
PURPOSE To up date the 1999 American Society of Clinical Oncology guideline for antiemetics in oncology .
Ondansetron for efficient emesis control during total body irradiation.
Ondansetron is a 5-hydroxytryptamine receptor antagonist which has shown activity in the prevention of emesis following cytotoxic and radiation therapy for cancer . We describe our experience using ondansetron in 25 patients undergoing fractionated total body irradiation ( TBI ) 12 Gy/3 days as conditioning for bone marrow transplantation .  Antiemetic efficiency was investigated during the 3 days of TBI prior to high-dose cytotoxic chemotherapy . Twenty-two of the 25 patients ( 88 % ) achieved sufficient emesis control with less than three emetic episodes whereas the remaining 12 % experienced three to five emetic events during their worst 24-h period . Eleven patients ( 44 % ) had complete control with no vomiting at all . Of 75 ' patient days ' , 52 ( 69 % ) were without any emesis , 20 ( 27 % ) were associated with one to two and only three ( 4 % ) with three to five emetic episodes . Headache occurred in four patients ( 16 % ) . No other significant adverse effects were seen , in particular no extrapyramidal reactions due to ondansetron . Our data confirm that ondansetron plays a major role in the antiemetic management of patients undergoing TBI
For persons receiving chemotherapy of high emetic risk , there is no group of patients for whom agents of lower therapeutic index are appropriate first-choice antiemetics .
In all patients receiving cisplatin and all other agents of high emetic risk , the two-drug combination of dexamethasone and aprepitant is recommended for the prevention of delayed emesis .
The Up date Committee no longer recommends the combination of a 5-HT3 serotonin receptor antagonist and dexamethasone for the prevention of delayed emesis after chemotherapeutic agents of high emetic risk .
PURPOSE To up date the 1999 American Society of Clinical Oncology guideline for antiemetics in oncology .